文献速递肝病

肝病中的肠-肝轴:治疗的病理生理基础

The gut-liver axis in liver disease: Pathophysiological basis for therapy.
PubMed 文献 · J Hepatol · 2019-10-14

本文综述了肠-肝轴在肝病中的病理生理作用,涉及酒精、非酒精性脂肪性肝病和肝硬化等。肠道屏障损伤和微生物代谢物参与疾病进展,针对肠道的益生菌、粪菌移植、FXR激动剂等为潜在治疗方向。

要点

  • 肠-肝轴通过门静脉和胆汁反馈双向互作,调控肝脏与肠道微生物稳态。
  • 酒精在多层面破坏肠道屏障,增加微生物暴露和肝脏炎症环境。
  • 微生物代谢物如三甲胺、次级胆汁酸、短链脂肪酸和乙醇参与NAFLD发病。

核心结论

  • 肠-肝轴在多种慢性肝病中起关键病理生理作用,针对其损伤环节的干预具有治疗潜力。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 酒精在肠道微生物组、黏液屏障、上皮屏障和抗菌肽产生等多层面破坏肠-肝轴。
  • 微生物代谢物三甲胺、次级胆汁酸、短链脂肪酸和乙醇参与非酒精性脂肪性肝病发病。
  • 肝硬化与肠道菌群显著改变及肠道屏障多层面损伤相关,后者与活菌移位、细菌感染和疾病进展有关。

临床怎么用

  • 识别每种慢性肝病中肠-肝轴主要受损环节,为干预提供靶点。
  • 新兴疗法包括益生菌、postbiotics、粪菌移植、碳纳米颗粒和FXR激动剂等。
  • 合成生物药物、靶向特定细菌的噬菌体及建立肠-肝物理屏障的疗法提供新思路。

局限性

  • 原文未明确报告综述的检索策略、纳入标准或证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The gut-liver axis refers to the bidirectional relationship between the gut and its microbiota, and the liver, resulting from the integration of signals generated by dietary, genetic and environmental factors. This reciprocal interaction is established by the portal vein which enables transport of gut-derived products directly to the liver, and the liver feedback route of bile and antibody secretion to the intestine. The intestinal mucosal and vascular barrier is the functional and anatomical structure that serves as a playground for the interactions between the gut and the liver, limiting the systemic dissemination of microbes and toxins while allowing nutrients to access the circulation and to reach the liver. The control of microbial communities is critical to maintaining homeostasis of the gut-liver axis, and as part of this bidirectional communication the liver shapes intestinal microbial communities. Alcohol disrupts the gut-liver axis at multiple interconnected levels, including the gut microbiome, mucus barrier, epithelial barrier and at the level of antimicrobial peptide production, which increases microbial exposure and the proinflammatory environment of the liver. Growing evidence indicates the pathogenetic role of microbe-derived metabolites, such as trimethylamine, secondary bile acids, short-chain fatty acids and ethanol, in the pathogenesis of non-alcoholic fatty liver disease. Cirrhosis by itself is associated with profound alterations in gut microbiota and damage at the different levels of defence of the intestinal barrier, including the epithelial, vascular and immune barriers. The relevance of the severe disturbance of the intestinal barrier in cirrhosis has been linked to translocation of live bacteria, bacterial infections and disease progression. The identification of the elements of the gut-liver axis primarily damaged in each chronic liver disease offers possibilities for intervention. Beyond antibiotics, upcoming therapies centred on the gut include new generations of probiotics, bacterial metabolites (postbiotics), faecal microbial transplantation, and carbon nanoparticles. FXR-agonists target both the gut and the liver and are currently being tested in different liver diseases. Finally, synthetic biotic medicines, phages that target specific bacteria or therapies that create physical barriers between the gut and the liver offer new therapeutic approaches.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Albillos A, de Gottardi A, Rescigno M, et al. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2019. PMID: 31622696. doi:10.1016/j.jhep.2019.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。